Andrea Servillo, Maria Vittoria Cicinelli, Cecilia Mularoni, Carlo La Spina, Francesco Bandello, Elisabetta Miserocchi
{"title":"单抗后药物性血管炎和脉络膜炎。","authors":"Andrea Servillo, Maria Vittoria Cicinelli, Cecilia Mularoni, Carlo La Spina, Francesco Bandello, Elisabetta Miserocchi","doi":"10.1016/j.oret.2025.05.020","DOIUrl":null,"url":null,"abstract":"<p><p>This study reports two cases of drug-induced immune-mediated retinal vasculopathy and choroiditis following intravitreal brolucizumab, highlighting its clinical features, severity, and irreversibility, emphasizing vigilant monitoring and multidisciplinary management to prevent vision-threatening complications.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Drug-induced Vasculitis and Choroiditis after Brolucizumab.\",\"authors\":\"Andrea Servillo, Maria Vittoria Cicinelli, Cecilia Mularoni, Carlo La Spina, Francesco Bandello, Elisabetta Miserocchi\",\"doi\":\"10.1016/j.oret.2025.05.020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study reports two cases of drug-induced immune-mediated retinal vasculopathy and choroiditis following intravitreal brolucizumab, highlighting its clinical features, severity, and irreversibility, emphasizing vigilant monitoring and multidisciplinary management to prevent vision-threatening complications.</p>\",\"PeriodicalId\":19501,\"journal\":{\"name\":\"Ophthalmology. Retina\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Retina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.oret.2025.05.020\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oret.2025.05.020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Drug-induced Vasculitis and Choroiditis after Brolucizumab.
This study reports two cases of drug-induced immune-mediated retinal vasculopathy and choroiditis following intravitreal brolucizumab, highlighting its clinical features, severity, and irreversibility, emphasizing vigilant monitoring and multidisciplinary management to prevent vision-threatening complications.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
